Nick P. France, M.D.

Senior Vice President, Clinical Development

Dr. France is an accomplished rare disease clinical drug developer with extensive clinical, regulatory and business development expertise across all phases of development.

He previously served as vice president and head of clinical research at ESCAPE Bio, where he helped lead the transformation of the company from a preclinical to a clinical organization and had responsibility for all aspects of global clinical development and translational medicine. Prior to ESCAPE, Dr. France held positions of increasing responsibility in global biopharma organizations with a focus on developing clinical and regulatory strategy and building high performing clinical groups in emerging and early-stage biotech companies. He was senior director, clinical development for neurosciences and rare diseases with Roivant Sciences and Axovant Sciences, and executive director, clinical development at Strongbridge Biopharma. Other prior roles included global clinical program director at CSL Behring, and clinical development director, neurosciences and rare diseases at GlaxoSmithKline. During his career, Dr. France has successfully led a number of clinical programs through regulatory meetings for pivotal stage studies and has served in clinical leadership roles on the development of several assets that achieved regulatory approval including migalastat, AFSTYLA and Retigabine. He currently serves as a scientific medical advisory board member for the INADCure Foundation.

Dr. France earned a B.S. in pharmacology from King’s College London (University of London) in the U.K. and his M.D. from the University of Warwick Medical School (U.K.) after which he trained in Pediatrics in London with a focus on Intensive Care Medicine. Dr. France is also a member of the Royal College of Pediatrics and Child Health.